Actively Recruiting
Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial
Led by China National Center for Cardiovascular Diseases · Updated on 2025-06-04
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating risk factors and prognosis differences in Chinese individuals under 45 years old with premature coronary artery disease. This observational cohort study aims to create a model predicting adverse events, such as cardiac death, heart attacks, strokes, and repeat procedures, over a two-year period. The study is led by the China National Center for Cardiovascular Diseases and focuses on understanding outcomes for different patient types without introducing any mandatory treatments. Participants will not receive any study treatments but will be observed over two years. Blood tests are scheduled at the one-year mark, and participants will have follow-up visits or telephone interviews at various intervals. The study collects detailed information on major adverse cardiac and cerebrovascular events (MACCE) and tracks their sensitivity and specificity in prediction. Additional outcomes include rates of death, heart attacks, revascularizations, stent thrombosis, strokes, and bleeding events, measured regularly throughout the two years. During the study, participants will undergo blood tests, outpatient visits, or phone interviews to monitor their health status. Researchers will assess the occurrence of cardiac events and other complications to develop a prediction model. The study involves no active intervention, focusing on observation and data collection for two years to better understand risk factors and outcomes in this patient group.
CONDITIONS
Brief Title
Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-45 years
- Clinically confirmed coronary artery disease with 50% or more narrowing in at least one major coronary artery or branch, verified by coronary angiography
- For patients with acute coronary syndrome or percutaneous coronary intervention, clinical stability meeting discharge criteria after treatment
- Voluntary participation with signed informed consent
You will not qualify if you...
- Heart transplant recipients
- Severe systemic diseases with life expectancy less than 1 year
- Previous participation in other drug or device trials without completing primary endpoint observation
- Unable to comply with follow-up due to conditions like dementia or severe psychiatric disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 years
Participants are monitored for cardiac events and health outcomes over time.
Assessments at 1 month, 6 months, 1 year, and 2 years
Trial Site Locations
Total: 1 location
1
FuWai Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jingjing Xu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here